Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Price Down 9.3%

Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report)'s stock price fell 9.3% during mid-day trading on Monday . The stock traded as low as $17.68 and last traded at $17.68. 1,992 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 7,694 shares. The stock had previously closed at $19.50.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Calliditas Therapeutics AB (publ) in a report on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Stock Performance

The company has a debt-to-equity ratio of 2.89, a quick ratio of 3.08 and a current ratio of 3.13. The stock has a market capitalization of $555.68 million, a P/E ratio of -11.37 and a beta of 1.51. The business has a 50-day moving average price of $20.80 and a 200 day moving average price of $20.65.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.02. The firm had revenue of $42.45 million during the quarter, compared to analyst estimates of $36.24 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 104.47% and a negative net margin of 38.72%. During the same quarter in the previous year, the firm earned ($0.01) EPS. As a group, sell-side analysts forecast that Calliditas Therapeutics AB will post 0.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

An institutional investor recently bought a new position in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. purchased a new position in Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 980 shares of the company's stock, valued at approximately $25,000. Institutional investors and hedge funds own 2.83% of the company's stock.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.